Pandemic Had Modest Effect on Early Childhood Development Milestones
By Elana Gotkine HealthDay Reporter
MONDAY, April 22, 2024 -- Modest changes were seen in early childhood development milestone achievement during the COVID-19 pandemic, according to a study published online April 22 in JAMA Pediatrics.
Sara B. Johnson, Ph.D., M.P.H., from the Johns Hopkins School of Medicine in Baltimore, and colleagues conducted a cohort study using an interrupted time-series analysis comparing prepandemic (March 1, 2018, to Feb. 29, 2020), interruption (March 1 to May 31, 2020), and intrapandemic (June 1, 2020, to May 30, 2022) periods among 50,205 children aged 0 to 5 years. Data were included from 134,342 Age-standardized Ages and Stages Questionnaire, Third Edition (ASQ) observations.
The researchers found that from prepandemic to intrapandemic, significant age-specific mean score decreases were observed in communication, problem-solving, and personal-social domains (−0.029, −0.018, and −0.016, respectively) in adjusted models. From prepandemic to intrapandemic, no changes were seen in fine or gross motor domains. Similar effect sizes were seen for infants aged 0 to 12 months for communication and problem-solving domains (−0.027 and −0.018, respectively). Compared with the prepandemic period, in the intrapandemic period, caregiver worries about the child increased slightly after accounting for age-standardized ASQ scores (rate ratio, 1.088); no changes were seen in caregiver concerns about the child's behavior. Modest changes in developmental screening scores were seen (2 to 3 percent), but this could translate to more than 1,500 additional recommended developmental referrals over baseline each month nationwide.
"Our findings provide reason for cautious optimism about the development of a generation of children exposed to the pandemic," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Further Support and Information on COVID-19
Read this next
Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms
WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.